Polymorphisms in XPD and hOGG1 and prostate cancer risk: a meta-analysis.
To examine the association between XPD and hOGG1 polymorphisms and prostate cancer (PCa) susceptibility. A comprehensive search was conducted to identify all case-control studies on the relationship between XPD and hOGG1 polymorphisms and PCa risk. Odds ratios (ORs) were used to investigate the strength of the associations. A total of 15 case-control studies including 5,765 cases and 6,270 controls were eligible for the meta-analyses. For XPD Asp312Asn, no evidence indicated that individuals carrying 312Asn had an increased risk of PCa. In subgroup analyses, Asp312Asn polymorphism was associated with PCa risk in Asian populations [OR = 2.09 and 95% CI = 1.39-3.14 for Asn/Asn vs. Asp/Asp; OR = 1.49 and 95% CI = 1.12-1.98 for (Asn/Asn+Asn/Asp) vs. Asp/Asp]. For XPD Lys751Gln, the individuals with 751Gln did not have increased PCa risk compared with those with 751Arg, and no association was found in the subgroup analyses. For hOGG1 Ser326Cys, no significant association between the polymorphism and PCa risk was observed in the overall analysis. However, Ser326Cys was significantly associated with PCa risk under homologous contrast in Caucasians and Asians. XPD Asp312Asn polymorphism is associated with PCa risk in Asians and hOGG1 Ser326Cys polymorphism is associated with PCa risk in Caucasians and Asians.